Axsome Therapeutics vs. Moderna: Which Biotech Stock Is a Better Buy in 2026?

Impact · against what's priced in

The article provides no new catalysts for Moderna or Merck, as the reported financial declines and strategic oncology goals are already fully reflected in their current valuations. Axsome shows strong revenue momentum and a stabilizing balance sheet, but lacks a price reconstruction to determine if these trajectories are already baked in.

MRK+0.00

Already priced in

The price assumes

mRNA cancer vaccine (Intismeran) with Keytruda in melanoma and broader cancers